Non-Invasive Prenatal Genetic Testing+gender (Plus)

NIPT –An Accurate First-Line Screen for Chromosomal Aneuploidies

- Early Detection - No Risk - High Accuracy - 

Uses a simple blood sample from the pregnant mother to screen for fetal chromosomal abnormalities, such as Down syndrome and Turner syndrome. It also offers optional early determination of the baby's sex in a safe, non-invasive way.

Noninvasive prenatal testing (NIPT) performed with next generation sequencing (NGS) provides reliable screening results for fetal chromosomal aneuploidies as early as 10 weeks gestation—from a single tube of maternal blood. Our NIPT Solution v2 takes advantage of powerful Illumina NGS technology to bring a whole-genome sequencing (WGS) approach to NIPT, expanding test menu options to include common aneuploidies (trisomies 21, 18, and 13), rare autosomal aneuploidies (RAAs), select sex chromosome aneuploidies (SCAs), and partial deletions and duplications, referred to as copy number variations (CNVs), that are ≥ 7 Mb. 

Primary targets:

• Trisomy 21 (Down syndrome)
• Trisomy 18 (Edwards syndrome)
• Trisomy 13 (Patau syndrome)
• Sex chromosome aneuploidies (e.g. Turner, Klinefelter)
• Fetal sex determination

Optional add-ons:

• 5 Microdeletion syndromes (e.g. 22q11.2)
• All chromosomes aneuploidies 

Flexible Options

Upgrade to gender reveal,microdeletion,all chromosomes, etc.